GlassScriptPhysician profile
Arpan Karki
NPI 1033780812
$1,989.20
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $285 · 2022: $899 · 2023: $737 · 2024: $68.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $766 · Education: $39.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $765.51 |
| Education | $39.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $498.61 | 2021-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $262.95 | 2021-2023 | Keytruda, Recarbrio, Zerbaxa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $227.28 | 2021-2024 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.15 | 2021-2023 | Jardiance |
| Gilead Sciences, INC. | $200.01 | 2022-2024 | Veklury |
| Abiomed | $144.80 | 2022 | |
| La Jolla Pharmaceutical Company | $138.13 | 2023 | Xerava |
| Horizon Therapeutics Plc | $117.68 | 2022 | |
| Alexion Pharmaceuticals, INC. | $110.73 | 2021-2022 | |
| Insmed, INC. | $44.96 | 2021-2022 | |
| Organon LLC | $22.05 | 2023 | Renflexis |
| Pfizer INC. | $12.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arpan Karki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.